SAB Biotherapeutics's total assets for Q3 2025 were $183.45M, a decrease of ― from the previous quarter. SABS total liabilities were $18.37M for the fiscal quarter, a ― a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.